Incyte vs. Hikma: Consent Judgment Secures Ruxolitinib Patent Protection in Landmark Pharma Case

Case Overview

The Parties

Patents at Issue

This case involved five U.S. patents covering ruxolitinib’s chemical composition, pharmaceutical formulations, and therapeutic applications as a JAK inhibitor, forming a layered IP fortress around Jakafi®:

• • U.S. Patent No. 7,598,257 — Chemical composition and therapeutic applications
• • U.S. Patent No. 8,415,362 — Pharmaceutical formulations of ruxolitinib
• • U.S. Patent No. 8,722,693 — Methods of treatment using ruxolitinib
• • U.S. Patent No. 8,822,481 — Specific dosage forms and regimens
• • U.S. Patent No. 8,829,013 — Further methods of use and formulations

The Verdict & Legal Analysis

Outcome

On October 27, 2025, the District Court entered a **consent judgment and permanent injunction** by stipulation of both parties. No damages were awarded—consistent with the pre-launch nature of the generic challenge—and no admission of infringement or invalidity was made.

The injunction prohibits Hikma and its successors from making, using, selling, offering to sell, importing, or distributing its ANDA product or any ruxolitinib-containing drug referencing NDA 202192 **until expiration of all five Patents-in-Suit**, unless specifically authorized by Incyte.

Key Legal Issues

The case was designated as an **infringement action**—the standard cause of action in Hatch-Waxman ANDA litigation under 35 U.S.C. § 271(e)(2), where the mere filing of an ANDA with a Paragraph IV certification constitutes a technical act of infringement. No court ruling on validity or infringement merits was reached; instead, both parties stipulated to judgment, indicating Hikma elected not to pursue full validity challenges through trial.

Several provisions of the consent judgment merit close analysis:

• • **Paragraph IV Certification Preserved:** The judgment expressly permits Hikma to maintain its existing Paragraph IV certification, meaning Hikma retains the ability to challenge patent validity through future proceedings.
• • **Section 271(e)(1) Safe Harbor Preserved:** The judgment does not restrict Hikma from engaging in research or regulatory activities permitted under the Hatch-Waxman safe harbor, preserving Hikma’s ability to continue development activities.
• • **FDA Approval Unaffected:** Critically, the judgment does not restrict FDA from approving ANDA No. 219768, meaning Hikma’s ANDA remains approvable. Market entry, not ANDA approval itself, is enjoined.

Strategic Takeaways

• • **For Patent Holders:** Layered pharmaceutical patent portfolios covering composition, formulation, and method-of-use claims create compounding litigation burdens for ANDA challengers. Early and aggressive Hatch-Waxman enforcement actions, backed by large litigation teams, signal credible commitment to defense and can accelerate settlement.
• • **For Generic Manufacturers:** The preservation of IPR rights within consent judgments is a critical negotiating point. Retaining the ability to challenge patents post-judgment provides a long-term strategic option, particularly where commercial launch timing and market size justify future investment in validity challenges.
• • **For R&D Teams:** Freedom-to-operate (FTO) analyses must account for layered patent families—not just lead composition-of-matter patents—before committing to generic development timelines and ANDA investment.